CAM
IDIX

Cormorant Asset Management’s IDENIX PHARMACEUTICALS INC IDIX Stock Holding History

Cormorant Asset Management’s Portfolio IDIX Stock Details IDIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-2,500,000
Closed -$15.1M – 63
2014
Q1 		$15.1M Sell
2,500,000
-425,000
-15% -$2.96M 3.47% 9
2013
Q4 		$17.5M Buy
+2,925,000
New +$13.5M 5.08% 8

Other funds holding IDIX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cormorant Asset Management's IDIX Position: Q2 2014 in Review

Cormorant Asset Management sold out of IDENIX PHARMACEUTICALS INC (IDIX) in Q2 2014, closing a stake of 2,500,000 shares — an estimated $15.1M sold.

Cormorant Asset Management first reported a position in IDIX in Q4 2013 and held it in 2 quarters. The position peaked at $17.5M in Q4 2013. 131 funds tracked by Wall St. Rank hold IDIX as of Q2 2014.

  • Cormorant Asset Management reported no remaining IDENIX PHARMACEUTICALS INC position as of Q2 2014 after selling out during the quarter.
  • Cormorant Asset Management sold 2,500,000 IDENIX PHARMACEUTICALS INC shares in Q2 2014, an estimated $15.1M.
  • Cormorant Asset Management first reported a position in IDENIX PHARMACEUTICALS INC in Q4 2013 and held it in 2 quarters.
  • Cormorant Asset Management's IDENIX PHARMACEUTICALS INC position peaked at $17.5M in Q4 2013.
  • 131 funds tracked by Wall St. Rank held IDENIX PHARMACEUTICALS INC as of Q2 2014.

Based on Cormorant Asset Management's 13F filing for Q2 2014, filed 14 Aug 2014.